Enliven Therapeutics, Inc. (ELVN)
↓ Download CSVKey ratios (FY2025)
-22.6%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$51.44M | -$41.70M | -$24.12M | — |
| Net Income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$51.38M | -$41.36M | -$23.46M | — |
| EPS (Diluted) | $-1.83 | $-1.89 | $-2.01 | $-12.05 | $-2.37 | — | — | — |
| Total Assets | $476.17M | $325.76M | $271.87M | $83.30M | $93.65M | $90.84M | $33.30M | — |
| Total Liabilities | $16.57M | $15.91M | $25.96M | $10.37M | $7.62M | $6.41M | $4.38M | — |
| Shareholders' Equity | $459.60M | $309.85M | $245.91M | -$76.83M | -$42.89M | $84.44M | -$48.85M | -$26.32M |
| Cash & Equivalents | $98.90M | $124.12M | $100.14M | $75.54M | $48.31M | $47.70M | $4.94M | — |
| Operating Cash Flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | -$46.77M | -$37.40M | -$21.88M | — |
| Capital Expenditures | $158.0K | $44.0K | $149.0K | $612.0K | $12.0K | $18.0K | $140.0K | — |
| Shares Outstanding | 59.44M | 48.94M | 41.29M | 3.57M | 26.29M | 17.55M | 702.5K | — |